ライフサイエンスコーパス: CTC

1 CTC >/=2 (hazard ratio [HR]: 2.5; 95% confidence interva

2 CTC >/=5 was associated with shorter survival of patient

3 CTC and CPC characterization in humans in vivo is still

4 CTC clusters with large number of CTCs were observed in

5 CTC detected patients with polyps of >/=6 mm with 44.0%

6 CTC detection alone was not associated with poor progres

7 CTC detection rate (37.2% vs 19.6%; P = 0.04) and count

8 CTC nonzero at baseline and 0 at 13 weeks (CTC0); CTC co

9 CTC results were revealed after endoscopic visualization

10 CTC+/AR-V7+ patients were more likely to have Gleason sc

11 CTCs are a minimally invasive source of clinical informa

12 CTCs are, especially at the early stages of cancer devel

13 CTCs were associated with more-aggressive tumor characte

14 CTCs were associated with tumor extent.

15 CTCs were classified into distinct subsets according to

16 CTCs were detected positive in all samples with 4 patien

17 CTCs were enumerated and analyzed for PD-L1 expression u

18 CTCs were identified by immunofluorescence using commerc

19 CTCs were isolated by size using a filtration-based devi

20 CTCs were isolated from the samples using magnetic separ

21 CTCs were quantified in PPB and IPVB in 23 consecutive s

22 CTCs were quantified with fluorescence-labeled antibodie

23 CTCs were separated from blood using magnetic beads coat

24 VM vessels are also observed in 9/10 CTC patient-derived explants (CDX), where molecular anal

25 in 18 additional patients (testing set, 112 CTC samples) and in six SCLC patient-derived CTC explant

26 containing 2-chlorotritylchloride linkers (2-CTC resin).

27 re prepared on the silica particles on the 2-CTC resin.

28 samples with 4 patients having more than 20 CTCs.

29 In 26 CTC-evaluable patients, taxane-induced decrease in %ARNL

30 erall survival (OS) than patients with 0.3-3 CTC/ml (P = 0.12).

31 Patients with >3 CTC/ml had a trend for worse median overall survival (OS

32 identified as high-risk groups exhibited >5 CTCs/15 mL in PPB and >50 CTCs/15 mL in IPVB.

33 0 at 13 weeks (CTC0); CTC conversion (>/= 5 CTCs at baseline, </= 4 at 13 weeks-the US Food and Drug

34 roups exhibited >5 CTCs/15 mL in PPB and >50 CTCs/15 mL in IPVB.

35 the size and EpCAM expression of over 2,500 CTCs from 38 patient samples obtained from breast, prost

36 After analysis of 88 CTCs isolated from 13 patients (training set), we genera

37 Integrative CNA analyses of 97 CTCs from 23 patients confirmed the convergence of CNAs

38 ich usually takes >6 months and results in a CTC expansion efficiency of <20%.

39 protein FzlC disrupts DeltaCTL bundling in a CTC-dependent manner.

40 ructed CPC, supporting the hypothesis that a CTC-CPC loop provides a substrate for cerebro-cerebellar

41 (+ v -) and AR-V7 detection (+ v -) using a CTC-based AR-V7 mRNA assay.

42 e review what we have recently learned about CTCs from pancreatic tumors, describing advances in thei

43 primary tumor cells but were present in all CTCs, suggesting a strong selection toward metastasis.

44 The associations among CTCs, cfDNA, and (18)F-FDG PET/CT-derived parameters wer

45 s revealed an epigenetic heterogeneity among CTCs and indicates tumor-specific active epigenetic regu

46 In subgroup analyses, CTC >/=2 (HR, 8.2; 95% CI: 1.8-57.5; P < 0.01) and CTC >

47 patients, 10 healthy donors) were analyzed; CTCs were present in patients with UICC stage IA-IV tumo

48 =2 (HR, 8.2; 95% CI: 1.8-57.5; P < 0.01) and CTC >/=5 (HR, 7.7; 95% CI: 1.4-42.9; P = 0.02) were both

49 idence interval [CI]: 1.1-5.4; P = 0.02) and CTC >/=5 (HR, 4.1; 95% CI: 1.4-10.8; P = 0.01) were both

50 d to mimic human capillary constrictions and CTC clusters obtained from patient and cancer cell origi

51 Conclusion The CTC0 and CTC conversion end points had the highest discriminatory

52 s Of the eight response end points, CTC0 and CTC conversion had the highest weighted c-indices, with

53 idoscopy every 10 years with annual FIT, and CTC every 5 years performed from ages 50 through 75 year

54 y after response to CCRT, initial stage, and CTC number (>/=21.0 cells/mL) played independent prognos

55 t EGFR promotes survival of prostate TIC and CTC that metastasize to bone, whereas HER2 supports the

56 7, and 14.6 months for CTC-, CTC+/AR-V7- and CTC+/AR-V7+ patients, respectively.

57 rognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

58 CCSCs and CTCs were detected (90% efficiency) and classified in ac

59 A major ribosome pause at CTC leucine codons in the native gene of FVIII HC was el

60 ith PDAC was therefore subject to size-based CTC-isolation (ISET).

61 Here we report that BCBM CTCs is enriched in a distinct sub-population of cells i

62 fied signaling pathways associated with BCBM CTCs that may have roles in potentiating BCBM.

63 tient-derived CTCs transcriptomes, for BCBM- CTCs that is different from primary tumors.

64 Associations between CTC, patient and tumor characteristics, and survival wer

65 The association between CTCs and prognosis in these patients was evaluated after

66 e to the "seed and soil" suitability between CTCs and bone.

67 vailable patient-derived CTCs, a biophysical CTC phenotype more lysis-resistant than breast cancer ce

68 tive oxygen species (ROS) in cultured breast CTCs triggers HBB induction, mediated through the transc

69 Cultured breast cancer CTC clusters containing between 2-100 + cells were recov

70 ic chip was utilized to identify and capture CTCs from metastatic breast, colon and non-small-cell lu

71 , these devices are ineffective at capturing CTC clusters, incapable of separating clusters from sing

72 using three separate prognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

73 atient data, week 13 circulating tumor cell (CTC) and prostate-specific antigen (PSA) response end po

74 ly taxane switch and circulating tumor cell (CTC) biomarkers to interrogate mechanisms of sensitivity

75 Conventional circulating tumor cell (CTC) detection strategies rely on cell surface marker Ep

76 ells (CCSCs), a rare circulating tumor cell (CTC) type, recently arose as a useful resource for monit

77 t the translation of circulating tumor cell (CTC)-based liquid biopsy assays that provide accurate mo

78 ely bind to a model circulating tumour cell (CTC) line, MCF-7, a metastatic breast cancer by targetin

79 ly aggressive NSCLC circulating tumour cell (CTC) patient derived explant (CDX) mouse model.

80 interaction between circulating tumor cells (CTC) and endothelial cells during extravasation is a cri

81 markers, micro-RNA, circulatory tumor cells (CTC) and some potential biomarkers are introduced briefl

82 as also observed in circulating tumor cells (CTC) during prostate cancer metastasis.

83 on 9,225 individual circulating tumor cells (CTC) from 179 unique metastatic castration-resistant pro

84 Circulating tumor cells (CTC) in the blood are hypothesized as the means of syste

85 or the detection of circulating tumor cells (CTC) using mass spectrometry (MS), through reporter-ion

86 e evaluated whether circulating tumor cells (CTC) with aberrant ALK-FISH patterns [ALK-rearrangement,

87 MT) is prominent in circulating tumor cells (CTC), but how it influences metastatic spread in this se

88 sis can be aided by circulating tumor cells (CTC), which also show potential to predict early relapse

89 revention targeting circulating tumor cells (CTC).

90 ood is purified for circulating tumor cells (CTCs) and clinical utility is typically limited to cell

91 Circulating tumor cells (CTCs) are a treasure trove of information regarding the

92 Circulating tumor cells (CTCs) are phenotypically heterogeneous, and in vitro ana

93 Circulating tumor cells (CTCs) are rare cancer cells that are shed from primary o

94 Circulating tumor cells (CTCs) are shed into the bloodstream by invasive cancers,

95 Direct analysis of circulating tumor cells (CTCs) can inform on molecular mechanisms underlying syst

96 t-7 (AR-V7) mRNA in circulating tumor cells (CTCs) correlated with poor outcomes from the use of abir

97 has been tested on circulating tumor cells (CTCs) derived from patient blood samples after ex vivo e

98 Circulating tumor cells (CTCs) detection, enumeration and characterization with m

99 em, platelets guard circulating tumor cells (CTCs) from immune elimination and promote their arrest a

100 characterization of circulating tumor cells (CTCs) from patients with cancer.

101 errations (CNAs) in circulating tumor cells (CTCs) from pretreatment SCLC blood samples.

102 ary tumor cells and circulating tumor cells (CTCs) from the same patient.

103 n of EpCAM-positive circulating tumor cells (CTCs) has allowed estimation of overall metastatic burde

104 Evaluation of circulating tumor cells (CTCs) has demonstrated clinical validity as a prognostic

105 Circulating tumor cells (CTCs) have been linked to cancer progression but are dif

106 Although circulating tumor cells (CTCs) have potential as diagnostic biomarkers for cancer

107 the hypothesis that circulating tumor cells (CTCs) in preoperative peripheral blood (PPB) and intraop

108 The detection of circulating tumor cells (CTCs) in the blood of cancer patients is a challenging t

109 promote survival of circulating tumor cells (CTCs) in the bloodstream by conferring resistance to the

110 lationships between circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a

111 cancer tissues and circulating tumor cells (CTCs) to investigate their role in defining prostate can

112 We assessed circulating tumor cells (CTCs) with epithelial and mesenchymal phenotypes as a po

113 PFS) and effects on circulating tumor cells (CTCs), bone biomarkers, serum prostate-specific antigen

114 ue for detection of circulating tumor cells (CTCs), due to their significance in prognosis and therap

115 rough the spread of circulating tumor cells (CTCs), is responsible for the majority of the cancer dea

116 ble in the blood as circulating tumor cells (CTCs), making them ideal targets to noninvasively profil

117 , and enrichment of circulating tumor cells (CTCs)-rare cells that enter the blood from solid tumors,

118 latforms focused on circulating tumor cells (CTCs).

119 Circulating tumour cells (CTCs) are rare tumour cells found in the circulatory sys

120 tastasis-competent circulating tumour cells (CTCs) experience oxidative stress in the bloodstream, bu

121 The role of circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients under

122 on the analyses of circulating tumour cells (CTCs) selected from the peripheral blood of cancer patie

123 rized by prevalent circulating tumour cells (CTCs), early metastasis and poor prognosis.

124 n is detectable in circulating tumour cells (CTCs), making it a potential prognostic biomarker by 'li

125 (OXI), tetracycline (TC), chlortetracycline (CTC) and doxycycline (DOX), respectively.

126 he photolytic fate of the chlortetracycline (CTC), ciprofloxacin (CIP), roxarsone (ROX), and sulfamet

127 Circulating tumor cell clusters (CTC clusters) are potent initiators of metastasis and po

128 aseline numbers of ALK-rearranged or ALK-CNG CTCs and PFS was observed.

129 The communication through coherence (CTC) hypothesis was originally proposed 10 years ago, st

130 CT colonography (CTC), when used in CRC screening, effectively identifies

131 tudies of computed tomographic colonography (CTC) with bowel preparation demonstrated per-person sens

132 testing, computed tomographic colonography (CTC), or colonoscopy starting at age 45, 50, or 55 years

133 or microfluidic sorting without compromising CTC yield and viability.

134 oach -conditional time-delayed correlations (CTC) - using the motions of all residue pairs of a prote

135 and include the cerebello-thalamo-cortical (CTC) and cortico-ponto-cerebellar (CPC) pathways.

136 three separate prognostic categories: CTC-, CTC+/AR-V7-, and CTC+/AR-V7+.

137 s were 15.0, 21.7, and 14.6 months for CTC-, CTC+/AR-V7- and CTC+/AR-V7+ patients, respectively.

138 onzero at baseline and 0 at 13 weeks (CTC0); CTC conversion (>/= 5 CTCs at baseline, </= 4 at 13 week

139 CTC samples) and in six SCLC patient-derived CTC explant tumors.

140 odel to identify the presence of HCC-derived CTCs in nine of 16 (56%) untreated patients with HCC ver

141 a unique signature, based on patient-derived CTCs transcriptomes, for BCBM- CTCs that is different fr

142 to assay sparingly available patient-derived CTCs, a biophysical CTC phenotype more lysis-resistant t

143 DH subpopulations within the patient-derived CTCs.

144 polymorphisms within human xenograft-derived CTCs in mouse models.

145 plication of RNA-based digital PCR to detect CTC-derived signatures may thus enable highly accurate t

146 flow cytometry protocol efficiently detected CTCs.

147 RNA-based digital CTC scoring was not correlated with the standard HCC ser

148 ts epithelial-mesenchymal transitioned (EMT) CTCs.

149 r chip will enable further studies examining CTC clusters in research and clinical applications.

150 We review studies that have expanded CTCs for testing of anticancer agents and how these appr

151 vimentin-positive and cytokeratin-expressing CTCs had decreased median time to recurrence compared wi

152 ositive for CTC >/=2 and 8 patients (9%) for CTC >/=5.

153 ng the perioperative period and assessed for CTC burden using a microfluidic device.

154 e and second-line NHT cohorts) were best for CTC- patients, intermediate for CTC+/AR-V7- patients, an

155 ere best for CTC- patients, intermediate for CTC+/AR-V7- patients, and worse for CTC+/AR-V7+ patients

156 and effective abortion botanic medicines for CTC-based metastatic chemoprevention.

157 ic decision making, and improved methods for CTC enumeration are asked for.

158 p times were 15.0, 21.7, and 14.6 months for CTC-, CTC+/AR-V7- and CTC+/AR-V7+ patients, respectively

159 Fifteen patients (17%) were positive for CTC >/=2 and 8 patients (9%) for CTC >/=5.

160 iate for CTC+/AR-V7- patients, and worse for CTC+/AR-V7+ patients.

161 n, a rapid and high-sensitivity approach for CTCs detection using an integrated microfluidic system,

162 cells from blood specimens and enriches for CTCs with well-preserved RNA.

163 venient use will be a promising platform for CTCs detection with potential clinical application.

164 wider electrochemical window and 70% higher CTC (charge transfer capacity) than Pt microelectrodes o

165 We also give context to how CTC isolation technologies enable downstream analysis of

166 Xenotransplantation of human CTC clusters into zebrafish showed similar reorganizatio

167 ometry was validated to efficiently identify CTCs.

168 se measure); a 30%, 50%, and 70% decrease in CTC count; and a 30%, 50%, and 70% decrease in PSA level

169 nificant association between the decrease in CTC number with ALK-CNG on crizotinib and a longer PFS (

170 The protocol's efficacy in CTC identification was validated with a recovery rate of

171 Depletion of HBB in CTC-derived cultures has minimal effects on primary tumo

172 zantinib was associated with improvements in CTC conversion, bone biomarkers, and post-random assignm

173 KRAS mutations in CTC and corresponding tumor were discordant in 11 of 26

174 ell migration and immune-related pathways in CTC clusters, suggesting survival advantage of clusters

175 expression or absence of EpCAM and/or CKs in CTCs.

176 than abruptly, converging toward the CNA in CTCs.

177 Aberrant ALK-FISH patterns were examined in CTCs using immunofluorescence staining combined with fil

178 grammed death-ligand 1 (PD-L1) expression in CTCs in colorectal and prostate cancer patients undergoi

179 oid circulating rare cells (CRCs), including CTCs and circulating tumor endothelial cells (CECs).

180 r of subtyping biomarkers on each individual CTC could dramatically enhance the clinical utility of B

181 r an eight-plex protein panel for individual CTCs derived from estrogen receptor-positive (ER+) breas

182 multigene expression profiling of individual CTCs from non-small-cell lung cancer (NSCLC) patients wi

183 t blood samples after ex vivo expansion into CTC clusters.

184 heral blood in early stages, we investigated CTCs in pulmonary vein blood accessed during surgical re

185 evice currently able to specifically isolate CTC clusters from single CTCs and blood cells relies on

186 We summarize technologies used to isolate CTCs from blood samples of patients with pancreatic canc

187 Isolated CTC from the HVB were subjected to gene expression analy

188 ntical approach, we observed in the isolated CTCs methylation patterns resembling more those of epith

189 ve CTCs (P < 0.01), but not mesenchymal-like CTCs (P = 0.39), was associated with poorer survival.

190 Because of the limited CTC numbers in peripheral blood in early stages, we inve

191 Low CTC phenotypic heterogeneity was associated with better

192 tly described a high-throughput microfluidic CTC-iChip, which efficiently depletes hematopoietic cell

193 The monolithic CTC-iChip enables debulking of blood samples at 15-20 mi

194 automated isolation of CTCs using monolithic CTC-iChip will enable the detailed measurement of their

195 Notably, CTC CNA profiles obtained at relapse from five patients

196 Serial molecular analysis of CTC shows promise for real-time patient monitoring and c

197 Deriving from a comprehensive analysis of CTC transcriptomes, we discovered a unique "circulating

198 multivariate analysis, the dynamic change of CTC with ALK-CNG was the strongest factor associated wit

199 After high-efficiency magnetic collection of CTC from blood, a single-cell nanowell array performs CT

200 (3)DOM* and (1)O2, enhancing degradation of CTC, ROX, and SMX.

201 ysis further characterizes the importance of CTC-based AR-V7 mRNA detection in predicting outcomes in

202 review, we focus on the current knowledge of CTC biology and the potential clinical implications.

203 gun to elucidate the molecular mechanisms of CTC generation, intravasation, survival, interactions wi

204 Accurate monitoring of CTC levels in blood provides clinical information suppor

205 The primary outcome was performance of CTC in the detection of colorectal adenomas and cancers

206 The performance of CTC isolation technologies depends on microfluidic archi

207 Clinically, we identified a subpopulation of CTC expressing vimentin and TF in the blood of metastati

208 ide and investigated the prognostic value of CTC detection (+ v -) and AR-V7 detection (+ v -) using

209 The negative predictive value of CTC for adenomas >/=6 mm was 90.7% (95% CI, 86.7-94.5) a

210 The analysis of CTCs has provided significant insight into the metastati

211 Assessment of CTCs may be useful for identifying CCA patients at risk

212 Studies on the biology of CTCs have begun to elucidate the molecular mechanisms of

213 Further capturing of CTCs from metastatic cancers patients revealed a positiv

214 se in patients with BCBM.Characterization of CTCs derived from breast cancer patients with brain meta

215 ains a challenge because of the low count of CTCs in the blood.

216 system by Veridex was used for detection of CTCs in peripheral blood.

217 in) and does not require prior enrichment of CTCs or depend on the use of growth factor supplements.

218 collected at baseline for the evaluation of CTCs and cfDNA.

219 ded is an atlas of high-definition images of CTCs from various cancer types, including uncommon CTCs

220 describe a new strategy for the isolation of CTCs from whole blood.

221 Unbiased, rapid, and automated isolation of CTCs using monolithic CTC-iChip will enable the detailed

222 ients, PV had significantly higher number of CTCs compared with preoperative Pe (P < 0.0001) and intr

223 The number of CTCs counted in PPB and IPVB was an independent risk fac

224 CTC clusters with large number of CTCs were observed in 50% of patients, with PV often rev

225 st that the dynamic change in the numbers of CTCs with ALK-CNG may be a predictive biomarker for criz

226 e, comparing single-cell RNA-Seq profiles of CTCs from breast, prostate and lung cancers, we observe

227 Protein profiling of CTCs would complement the recent advances in enumeration

228 The clinical and functional significance of CTCs is still under investigation.

229 understanding the biological significance of CTCs, and summarizes emerging methods for identifying, i

230 Additionally, the study of CTCs has exposed dramatic intrapatient and interpatient

231 However, a thorough understanding of CTCs associated with breast cancer brain metastasis (BCB

232 e of epithelial to mesenchymal transition on CTCs through platelet secretion of transforming growth f

233 ay be due to differences in study designs or CTC protocols.

234 r surgery, participants underwent outpatient CTC plus CT, followed by same-day OC.

235 ogene homolog (KRAS) mutations in pancreatic CTC and corresponding tumors, and evaluated their signif

236 in vivo Talin1 expression levels in patient CTC's correlated with prognosis and therapy response.

237 r (CTL), and a C-terminal conserved peptide (CTC).

238 pacity to report protein expression on a per CTC basis and two statistically distinct GAPDH subpopula

239 blood, a single-cell nanowell array performs CTC mutation profiling using modular gene panels.

240 Positive CTC scores declined in treated Nine of 32 (28%) patients

241 The presence of cytokeratin-positive CTCs (P < 0.01), but not mesenchymal-like CTCs (P = 0.39

242 nd coagulation that may provide EMT-positive CTCs with enhanced colonizing properties.

243 port metastatic colonization of EMT-positive CTCs.

244 (epithelial cell adhesion molecule) positive CTCs from blood.

245 Patients whose samples had AR-V7-positive CTCs before ARS inhibition had resistant posttherapy PSA

246 ts with or without pretherapy AR-V7-positive CTCs treated with a taxane.

247 AR-V7-positive CTCs were found in 34 samples (18%), including 3% of fir

248 shorter OS than those without AR-V7-positive CTCs.

249 n specially designed microwells that promote CTC cluster formation within 2 weeks, with an overall cl

250 This study proposes CTC biomarkers and signaling pathways implicated in BCBM

251 family was significantly higher in prostate CTCs.

252 while yielding an output of highly purified CTCs.

253 The ability to precisely detect and quantify CTCs and ctDNA could minimize invasive procedures and im

254 Overall, the results show that quantifying CTC phenotypic heterogeneity can help inform the choice

255 We show that SCLC patients (37/38) have rare CTC subpopulations co-expressing vascular endothelial-ca

256 owing ROS exposure, and dramatically reduces CTC-derived lung metastases.

257 n depth interrogation of clinically relevant CTCs.

258 lance population 1 year following resection, CTC was inferior to OC for detecting patients with polyp

259 ogies enable downstream analysis of selected CTCs in terms of detecting genetic mutations and gene ex

260 Colonoscopy, flexible sigmoidoscopy, CTC, and stool tests have differing levels of evidence t

261 we applied multiplexed-scAEBS to 159 single CTCs from 11 patients with metastatic breast and six wit

262 pecifically isolate CTC clusters from single CTCs and blood cells relies on the batch immobilization

263 tive for Ki67 expression in PV having single CTCs as opposed to clusters.

264 partmentalize and analyze hundreds of single CTCs.

265 Targeted single-CTC proteomics with the capacity for archivable, multipl

266 itation constitutes a sensitive and specific CTC readout, enabling high-throughput clinical applicati

267 the specific fluors of fluorescently stained CTCs followed by sequential restaining with additional b

268 their arrest at the endothelium, supporting CTC extravasation into secondary sites.

269 Surprisingly, CTCs harbored various KRAS mutations in codon 12 and 13.

270 ificantly higher percentage of patients than CTC conversion.

271 However, it is currently assumed that CTC clusters are too large to pass through narrow vessel

272 We hypothesized that CTCs are associated with poor survival of patients with

273 The CTC number of EC patients is significantly higher (P = 0

274 The CTC number was calculated and analysed for survival impa

275 mately 6 min), followed by incubation of the CTC clusters for 48 h before analysis.

276 aled novel interactions with domain 2 of the CTC protein, a feature typical to various Gram-positive

277 -hazards regression analysis showed that the CTC count in PPB or IPVB was an independent risk factor

278 e CTC0 end point, compared with 51% with the CTC conversion end point.

279 lign circumferentially in the cell, with the CTC mediating attachment to membrane-associated division

280 ation technologies utilize properties of the CTCs themselves such as surface antigens (e.g., epitheli

281 atients with a KRAS (G12V) mutation in their CTC (n = 14) had a trend to better median OS (24.5 month

282 ad differentially and sequentially with this CTC-derived material.

283 Thus, CTCs isolated from early stages of lung cancer are predi

284 atients, outcomes were assessed according to CTC levels at surgery.

285 with quantitative indices to compare CPC to CTC pathways in healthy subjects.

286 ansforming growth factor beta in response to CTC activation.

287 rker endpoint was analysis of post-treatment CTCs to confirm the hypothesis that clinical response wa

288 ing tumor were discordant in 11 of 26 "tumor-CTC-pairs" (42%), while 15 (58%) had a matching mutation

289 In other cancer types, CTCs are generally rare and noninvasive molecular detect

290 rom various cancer types, including uncommon CTCs captured only by broadly inclusive nonenrichment te

291 ue, complementary taxonomy for understanding CTC biology and ascertaining clinical impact.

292 clusions and Relevance: The results validate CTC nuclear expression of AR-V7 protein in men with mCRP

293 uidic chip that isolates and recovers viable CTC clusters from blood.

294 vice to allow size-based isolation of viable CTCs using hydrodynamic forces that are present in curvi

295 nt transformation mechanism for CIP, whereas CTC, ROX, and SMX were sensitized by (3)DOM* and (1)O2.

296 med a prospective study to determine whether CTC, concurrent with CT, could substitute for OC in CRC

297 s size greater than 5 cm was associated with CTC shedding from established liver metastases in the tr

298 cells, among the last cells to interact with CTCs, confer anti-metastatic protection.

299 ficient to suppress intracellular ROS within CTCs.

300 to recurrence compared with patients without CTCs (P = 0.02).